Kamada (KMDA) versus The Competition Head to Head Contrast
Kamada (NASDAQ: KMDA) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Kamada to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
This is a summary of current ratings and target prices for Kamada and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Kamada currently has a consensus price target of $8.50, indicating a potential upside of 70.00%. As a group, “Biopharmaceuticals” companies have a potential upside of 8.27%. Given Kamada’s stronger consensus rating and higher possible upside, equities analysts plainly believe Kamada is more favorable than its competitors.
This table compares Kamada and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
7.3% of Kamada shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Kamada and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Kamada||$87.83 million||$1.94 million||-83.32|
|Kamada Competitors||$579.30 million||$241.72 million||-6.51|
Kamada’s competitors have higher revenue and earnings than Kamada. Kamada is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Kamada has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Kamada’s competitors have a beta of 1.28, suggesting that their average share price is 28% more volatile than the S&P 500.
Kamada competitors beat Kamada on 7 of the 12 factors compared.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
Receive News & Stock Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related stocks with our FREE daily email newsletter.